Código QR

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients

Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1. Aryl hydrocarbon receptor interacting protein (AIP) mutations are associated with an aggressive, inheritable form of acromegaly that responds poorly to SST2-specific somatostatin analogs (SSA). The role of pasireotide,...

Descrición completa

Gardado en:
Principais autores: Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, Albert Beckers
Formato: Artigo
Idioma:Inglês
Publicado: Bioscientifica 2019-04-01
Series:Endocrine Connections
Assuntos:
acromegaly
AIP
somatostatin analog
FIPA
resistant
pituitary adenoma
pasireotide
octreotide
lanreotide
thyroid cancer
Acceso en liña:https://ec.bioscientifica.com/view/journals/ec/8/4/EC-19-0004.xml
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares